Skip to Content

'
Guang Yang, MD, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1984 Beijing Medical University, Beijing, China, PhD, Biomedical Sciences Department of Histology & Embryology
1976 Beijing Medical University, Beijing, China, MD, Medicine

Honors and Awards

1995 BPH Preclinical Research Award, Pfizer Company
1990 Postdoctoral Fellowship Award, Canadian Rick and Hanson Foundation
1986-1988 Forgarty International Research Fellowship Award, NIA, NIH
1985 Beijing Science Advancement Award, Education Ministry- Beijing, China

Selected Publications

Peer-Reviewed Original Research Articles

1. Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. e-Pub 6/2016. PMID: 27331874.
2. Karanika S, Karantanos T, Kurosaka S, Wang J, Hirayama T, Yang G, Park S, Golstov AA, Tanimoto R, Li L, Thompson TC. GLIPR1-?TM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Mol Cancer 14:122, 2015. e-Pub 6/2015. PMCID: PMC4484888.
3. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting Poly(ADP-Ribose) Polymerase and the c-Myb-Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer. Sci Signal 7(326):ra47, 5/20/2014. e-Pub 5/20/2014. PMID: 24847116.
4. Karantanos T, Tanimoto R, Edamura K, Hirayama T, Yang G, Golstov AA, Wang J, Kurosaka S, Park S, Thompson TC. Systemic GLIPR1-?TM protein as a novel therapeutic approach for prostate cancer. Int J Cancer 134(8):2003-13, 4/15/2014. e-Pub 11/1/2013. PMCID: PMC3942887.
5. Fujita T, Satoh T, Timme TL, Hirayama T, Zhu JX, Kusaka N, Naruishi K, Yang G, Goltsov A, Wang J, Vlachaki MT, Teh BS, Brian Butler E, Thompson TC. Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models. Urol Oncol 32(2):92-100, 2/2014. e-Pub 2/2013. PMCID: PMC3871954.
6. Li L, Yang G, Ren C, Tanimoto R, Hirayama T, Wang J, Hawke D, Kim SM, Lee JS, Goltsov AA, Park S, Ittmann MM, Troncoso P, Thompson TC. Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol 7(3):484-96, 6/2013. e-Pub 12/2012. PMCID: PMC3907183.
7. Tahir SA, Yang G, Goltsov A, Song KD, Ren C, Wang J, Chang W, Thompson TC. Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res 73(6):1900-11, 3/2013. e-Pub 1/2013. PMCID: PMC3688259.
8. Yang G, Goltsov AA, Ren C, Kurosaka S, Edamura K, Logothetis R, DeMayo FJ, Troncoso P, Blando J, DiGiovanni J, Thompson TC. Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10(2):218-29, 2/2012. e-Pub 12/2011. PMCID: PMC3908884.
9. Li L, Ren C, Yang G, Fattah EA, Goltsov AA, Kim SM, Lee JS, Park S, Demayo FJ, Ittmann MM, Troncoso P, Thompson TC. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res 71(24):7694-704, 12/15/2011. e-Pub 10/24/2011. PMCID: PMC3813470.
10. Floryk D, Kurosaka S, Tanimoto R, Yang G, Goltsov A, Park S, Thompson TC. Castration-induced changes in mouse epididymal white adipose tissue. Mol Cell Endocrinol 345(1-2):58-67, 10/2011. e-Pub 7/2011. PMCID: PMC3867123.
11. Tabata K, Kurosaka S, Watanabe M, Edamura K, Satoh T, Yang G, Abdelfattah E, Wang J, Goltsov A, Floryk D, Thompson TC. Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. Gene Ther 18(10):969-978, 10/2011. e-Pub 4/2011. PMCID: PMC3881531.
12. Yang G, Park S, Cao G, Goltsov A, Ren C, Truong LD, Demayo F, Thompson TC. MMTV promoter-regulated caveolin-1 overexpression yields defective parenchymal epithelia in multiple exocrine organs of transgenic mice. Exp Mol Pathol 89(1):9-19, 8/2010. e-Pub 4/2010. PMCID: PMC3881545.
13. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis 13(1):6-11, 3/2010. e-Pub 7/7/2009. PMCID: PMC2887695.
14. Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC. Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res 7(11):1781-91, 11/2009. e-Pub 11/10/2009. PMCID: PMC3881562.
15. Watanabe M, Yang G, Cao G, Tahir SA, Naruishi K, Tabata K, Fattah EA, Rajagopalan K, Timme TL, Park S, Kurosaka S, Edamura K, Tanimoto R, Demayo FJ, Goltsov AA, Thompson TC. Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol Cancer Res 7(9):1446-55, 9/2009. e-Pub 9/8/2009. PMCID: PMC2887686.
16. Tabata K, Watanabe M, Naruishi K, Edamura K, Satoh T, Yang G, Abdel Fattah E, Wang J, Goltsov A, Floryk D, Soni SD, Kadmon D, Thompson TC. Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer Prostatic Dis 12(3):301-9, 2009. e-Pub 12/23/2008. PMID: 19104507.
17. Yang G, Timme TL, Naruishi K, Fujita T, Fattah el MA, Cao G, Rajagopalan K, Rajocopolan K, Troung LD, Thompson TC. Mice with cav-1 gene disruption have benign stromal lesions and compromised epithelial differentiation. Exp Mol Pathol 84(2):131-40, 4/2008. e-Pub 8/31/2007. PMID: 18358473.
18. Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, Fattah el MA, Kadmon D, Thompson TC. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 68(3):731-9, 2/1/2008. PMID: 18245473.
19. Li L, Abdel Fattah E, Cao G, Ren C, Yang G, Goltsov AA, Chinault AC, Cai WW, Timme TL, Thompson TC. Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling. Cancer Res 68(2):434-43, 1/15/2008. PMID: 18199537.
20. Yang G, Addai J, Wheeler TM, Frolov A, Miles BJ, Kadmon D, Thompson TC. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol 38(11):1688-95, 11/2007. PMID: 17707459.
21. Wang H, Yang G, Timme TL, Fujita T, Naruishi K, Frolov A, Brenner MK, Kadmon D, Thompson TC. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther 14(10):819-27, 10/2007. PMID: 17627292.
22. Fujita T, Timme TL, Tabata K, Naruishi K, Kusaka N, Watanabe M, Abdelfattah E, Zhu JX, Ren C, Ren C, Yang G, Goltsov A, Wang H, Vlachaki MT, Teh BS, Butler EB, Thompson TC. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. Gene Ther 14(3):227-36, 2/2007. PMID: 17024109.
23. Naruishi K, Timme TL, Kusaka N, Fujita T, Yang G, Goltsov A, Satoh T, Ji X, Tian W, Abdelfattah E, Men T, Watanabe M, Tabata K, Thompson TC. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther 13(7):658-63, 7/2006. PMID: 16485011.
24. Sule N, Yakupoglu U, Shen SS, Krishnan B, Yang G, Lerner S, Sheikh-Hamad D, Truong LD. Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study. Am J Surg Pathol 29(4):443-51, 4/2005. PMID: 15767796.
25. Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 103(6):1186-94, 3/2005. PMID: 15712208.
26. Lai HH, Boone TB, Yang G, Smith CP, Kiss S, Thompson TC, Somogyi GT. Loss of caveolin-1 expression is associated with disruption of muscarinic cholinergic activities in the urinary bladder. Neurochem Int 45(8):1185-93, 12/2004. PMID: 15380628.
27. Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M, Wheeler T, Harper W. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10(19):6572-8, 10/1/2004. PMID: 15475446.
28. Yang G, Addai J, Tian WH, Frolov A, Wheeler TM, Thompson TC. Reduced infiltration of class A scavenger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res 64(6):2076-82, 3/15/2004. PMID: 15026346.
29. Ren C, Li L, Yang G, Timme TL, Goltsov A, Ren C, Ji X, Addai J, Luo H, Ittmann MM, Thompson TC. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res 64(3):969-76, 2/1/2004. PMID: 14871827.
30. Satoh T, Saika T, Ebara S, Kusaka N, Timme TL, Yang G, Wang J, Mouraviev V, Cao G, Fattah el MA, Thompson TC. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res 63(22):7853-60, 11/15/2003. PMID: 14633713.
31. Cao G, Yang G, Timme TL, Saika T, Truong LD, Satoh T, Goltsov A, Park SH, Men T, Kusaka N, Tian W, Ren C, Wang H, Kadmon D, Cai WW, Chinault AC, Boone TB, Bradley A, Thompson TC. Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol 162(4):1241-8, 4/2003. PMID: 12651616.
32. Satoh T, Yang G, Egawa S, Addai J, Frolov A, Kuwao S, Timme TL, Baba S, Thompson TC. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 97(5):1225-33, 3/1/2003. PMID: 12599229.
33. Satoh T, Timme TL, Saika T, Ebara S, Yang G, Wang J, Ren C, Kusaka N, Mouraviev V, Thompson TC. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther 14(2):91-101, 1/20/2003. PMID: 12614561.
34. Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC, Harper JW. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 8(11):3419-26, 11/2002. PMID: 12429629.
35. Mouraviev V, Li L, Tahir SA, Yang G, Timme TM, Goltsov A, Ren C, Satoh T, Wheeler TM, Ittmann MM, Miles BJ, Amato RJ, Kadmon D, Thompson TC. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol 168(4 Pt 1):1589-96, 10/2002. PMID: 12352463.
36. Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, Wang J, Timme TL, Aguilar-Cordova E, Thompson TC. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters. Prostate Cancer Prostatic Dis 5(4):316-25, 2002. PMID: 12627218.
37. Pramudji C, Shimura S, Ebara S, Yang G, Wang J, Ren C, Yuan Y, Tahir SA, Timme TL, Thompson TC. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clin Cancer Res 7(12):4272-9, 12/2001. PMID: 11751529.
38. Miles BJ, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G, Adler HL, Kernen K, Pramudji CK, Satoh T, Gdor Y, Ren C, Ayala G, Wheeler TM, Butler EB, Kadmon D, Thompson TC. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 12(16):1955-67, 11/1/2001. PMID: 11686937.
39. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 61(11):4386-92, 6/2001. PMID: 11389065.
40. Thompson TC, Timme TL, Ebara S, Satoh T, Yang G, Wang J, Miles BJ, Ayala G, Wheeler TM, Kadmon D. In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther 1(3):481-95, 5/2001. PMID: 11727520.
41. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD, Thompson TC. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 61(10):3882-5, 5/2001. PMID: 11358800.
42. Nasu Y, Bangma CH, Hull GW, Yang G, Wang J, Shimura S, McCurdy MA, Ebara S, Lee HM, Timme TL, Thompson TC. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer Prostatic Dis 4(1):44-55, 2001. PMID: 12497062.
43. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 60(20):5857-61, 10/15/2000. PMID: 11059783.
44. Hull GW, Mccurdy MA, Nasu Y, Bangma CH, Yang G, Shimura S, Lee HM, Wang J, Albani J, Ebara S, Sato T, Timme TL, Thompson TC. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res 6(10):4101-9, 10/2000. PMID: 11051263.
45. Yang G, Addai J, Ittmann M, Wheeler TM, Thompson TC. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res 6(9):3430-3, 9/2000. PMID: 10999725.
46. Thompson TC, Timme TL, Park SH, Yang G, Ren C. Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease. Prostate 43(4):248-54, 6/1/2000. PMID: 10861743.
47. Stepanova L, Yang G, DeMayo F, Wheeler TM, Finegold M, Thompson TC, Harper JW. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene 19(18):2186-93, 4/27/2000. PMID: 10822368.
48. Shaker MR, Yang G, Timme TL, Park SH, Kadmon D, Ren C, Ji X, Lee HM, Sehgal I, Anzano M, Sporn MB, Thompson TC. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis 18(5):429-38, 2000. PMID: 11467776.
49. Thompson TC, Yang G. Regulation of apoptosis in prostatic disease. Prostate Suppl 9:25-8, 2000. PMID: 11056499.
50. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59(22):5719-23, 11/1999. PMID: 10582690.
51. Erdamar S, Yang G, Harper JW, Lu X, Kattan MW, Thompson TC, Wheeler TM. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol 12(8):751-5, 8/1999. PMID: 10463475.
52. Nasu Y, Bangma CH, Hull GW, Lee HM, Hu J, Wang J, McCurdy MA, Shimura S, Yang G, Timme TL, Thompson TC. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther 6(3):338-49, 3/1999. PMID: 10435084.
53. Hall SJ, Mutchnik SE, Yang G, Timme TL, Nasu Y, Bangma CH, Woo SL, Shaker M, Thompson TC. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther 6(1):54-63, Jan-Feb, 1/1999. PMID: 10078964.
54. Thompson TC, Timme TL, Li L, Goltsov A, Yang G. Caveolin-1: complex and provocative therapeutic target in prostate cancer and potentially other malignancies. Emerging Therapeutic Targets 3:337-346, 1999.
55. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J, Thompson TC. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 4(9):1062-64, 9/1998. PMID: 9734401.
56. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4(8):1873-80, 8/1998. PMID: 9717814.
57. Hampel OZ, Kattan MW, Yang G, Haidacher SJ, Saleh GY, Thompson TC, Wheeler TM, Marcelli M. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J Urol 159(6):2220-5, 6/1998. PMID: 9598573.
58. Ren C, Yang G, Timme TL, Wheeler TM, Thompson TC. Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res 58(6):1285-90, 3/15/1998. PMID: 9515817.
59. Stapleton AM, Zbell P, Kattan MW, Yang G, Wheeler TM, Scardino PT, Thompson TC. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 82(1):168-75, 1/1/1998. PMID: 9428494.
60. Yang G, Timme TL, Park SH, Thompson TC. Transforming growth factor beta 1 transduced mouse prostate reconstitutions: I. Induction of neuronal phenotypes. Prostate 33(3):151-6, 11/1/1997. PMID: 9365541.
61. Yang G, Timme TL, Park SH, Wu X, Wyllie MG, Thompson TC. Transforming growth factor beta 1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin. Prostate 33(3):157-63, 11/1/1997. PMID: 9365542.
62. Todd D, Yang G, Brown RW, Cao J, D'Agati V, Thompson TS, Truong LD. Apoptosis in renal cell carcinoma: detection by in situ end-labeling of fragmented DNA and correlation with other prognostic factors. Hum Pathol 27(10):1012-7, 10/1996. PMID: 8892583.
63. Yang G, Wheeler TM, Kattan MW, Scardino PT, Thompson TC. Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Cancer 78(6):1267-71, 9/15/1996. PMID: 8826950.
64. Stapleton AM, Williams RH, Timme TL, Yang G, Truong LD, Thompson TC. Human cytomegalovirus is not implicated in benign prostatic hyperplasia: a study using immunohistochemistry and the polymerase chain reaction. J Urol 156(2 Pt 1):542-5, 8/1996. PMID: 8683733.
65. Truong LD, Petrusevska G, Yang G, Gurpinar T, Shappell S, Lechago J, Rouse D, Suki WN. Cell apoptosis and proliferation in experimental chronic obstructive uropathy. Kidney Int 50(1):200-7, 7/1996. PMID: 8807589.
66. Williams RH, Stapleton AM, Yang G, Truong LD, Rogers E, Timme TL, Wheeler TM, Scardino PT, Thompson TC. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res 2(4):635-40, 4/1996. PMID: 9816213.
67. Timme TL, Yang G, Rogers E, Kadmon D, Morganstern JP, Park SH, Thompson TC. Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Lab Invest 74(4):747-60, 4/1996. PMID: 8606485.
68. Eastham JA, Chen SH, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SL, Thompson TC. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 7(4):515-23, 3/1/1996. PMID: 8800746.
69. Yang G, Stapleton AM, Wheeler TM, Truong LD, Timme TL, Scardino PT, Thompson TC. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res 2(2):399-401, 2/1996. PMID: 9816183.
70. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55(22):5151-5, 11/15/1995. PMID: 7585563.
71. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1(10):1111-8, 10/1995. PMID: 9815901.
72. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, Yang G. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 10(5):869-79, 3/2/1995. PMID: 7534899.
73. Greene DR, Taylor SR, Aihara M, Yoshida K, Egawa S, Park SH, Timme TL, Yang G, Scardino PT, Thompson TC. DNA ploidy and clonal selection in ras + myc-induced mouse prostate cancer. Int J Cancer 60(3):395-9, 1/27/1995. PMID: 7829250.
74. Aihara M, Scardino PT, Truong LD, Wheeler TM, Goad JR, Yang G, Thompson TC. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer 75(2):522-9, 1/15/1995. PMID: 7529128.
75. Thompson TC, Timme TL, Park SH Ren C, Baley PA, Eastham JA, Sehgal I, Yang G. Tissue and cell-cell interactions in prostate cancer progression. Cancer 75(Supplement):1885-1891, 1995.
76. Timme TL, Yang G, Truong LD, Kadmon D, Park SH, Thompson TC. Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World J Urol 13(6):324-8, 1995. PMID: 9116750.
77. Yang G, Wang E. Terminin (Tp 63/60), a novel cell senescence-related protein, is present in the aging human hippocampus. Brain Res 644(2):188-96, 5/2/1994. PMID: 8050030.
78. Schipper HM, Yang G, Wang E. Expression of terminin, a senescence-related cytoplasmic protein, in the aging rat brain. Brain Res 635(1-2):224-30, 1/28/1994. PMID: 8173959.
79. Yang G, Wang E. Expression of terminin in the rat brain during neuronal differentiation. Brain Res 615(1):71-9, 6/25/1993. PMID: 8364727.
80. Yang G, Douville P, Gee S, Carbonetto S. Nonintegrin laminin receptors in the nervous system: evidence for lack of a relationship to P40. J Neurobiol 23(5):491-506, 7/1992. PMID: 1279113.
81. Koistinaho J, Yang G. C-fos protein induction in the rat and hamster pineal gland after onset of darkness. Histochemistry 95:115-121, 1991.
82. Yang GA, Koistinaho J. Age-related increase in c-fos expression in the sympathetic neurons of the rat superior cervical ganglion. Brain Res 533(2):338-43, 11/19/1990. PMID: 2126977.
83. Yang GA, Koistinaho J, Iadarola M, Shenhua-Zhu M, Hervonen A. Administration of adrenocorticotropic hormone (ACTH) enhances Fos expression in the rat adrenal cortex. Regul Pept 30(1):21-31, 8/21/1990. PMID: 2171048.
84. Koistinaho J, Roivainen R, Yang G. Circadian rhythm in c-fos protein expression in the rat adrenal cortex. Mol Cell Endocrinol 71(1):R1-6, 5/28/1990. PMID: 2114328.
85. Yang G, Matocha MF, Rapoport SI. Increased numbers of extra-adrenal chromaffin cells in the abdominal paraganglia of senescent F344 rats: a possible role for the glucocorticoid receptor. Cell Tissue Res 259(2):233-8, 2/1990. PMID: 2337922.
86. Koistinaho J, Yang G. Induction of c-fos protein-like immunoreactivity in the rat and hamster pineal gland after the onset of darkness. Histochemistry 95(1):73-6, 1990. PMID: 2126785.
87. Yang G, Koistinaho J, Zhu SH, Hervonen A. Induction of c-fos-like protein in the rat adrenal cortex by acute stress--immunocytochemical evidence. Mol Cell Endocrinol 66(2):163-70, 10/1989. PMID: 2558926.
88. Yang G, Koistinaho J, Zhu S, Hervonen A. Light and electron microscopic evidences of the presence of c-fos-like immunoreactivity in the rat adrenal cortex. Histochemistry 93(2):217-21, 1989. PMID: 2515172.
89. Yang G, Matocha MF, Rapoport SI. Localization of glucocorticoid receptor messenger ribonucleic acid in hippocampus of rat brain using in situ hybridization. Mol Endocrinol 2(8):682-5, 8/1988. PMID: 3211154.
90. Yang G, Li ZT. Histochemical and ultrastructural changes in SIF cells after electrical stimulation of the greater splanchnic nerves. Sheng Li Xue Bao 39(1):54-60, 2/1987. PMID: 2955520.
91. Yang G, Li Z. A quantitative ultrastructural comparison between the chromaffin and the small granules-containing (SGC) cells in guinea pig adrenal medulla. Acta Anatomica Sinica 17(2):60-64, 1986.
92. Yang G, Li Z. Computer programming of the morphometric analyses on the small-granulated structures in transmission electron microscopic (TEM) photomicrographs. Medical Physics (Shijazhuang) 6:19-24, 1986.
93. Yang G, Li Z. Stereological quantitation of the cell organelles in SIF cells of the guinea pig celiac ganglia. Acta Zoologica Sinica 32(1):40-47, 1986.
94. Yang G, Li Z. The changes in catecholamine content, MAO and TPPase activities of the SIF cells in the guinea pig celiac ganglia following electrical stimulation on the splanchnic nerve. J Physiol (Shanghai) 19:71-76, 1986.
95. Yang G, Li Z. Consecutive demonstration of catecholamine fluorescence and SDH activity in the catecholamines-containing cells on cryostat sections. J Anatomy (Shanghai) 8:172-178, 1985.
96. Yang G, Li Z. Ultrastructural localization of the MAO and TPPase activities in catecholamine-containing cells of the sympatho-adrenomedullary system of guinea pig. Acta Anatomica Sinica 16:165-171, 1985.
97. Yang G, Li Z. An ultrastructural study of the SIF cells in celiac ganglion of guinea pig, with special reference to cytochemical localization of the acid phosphatase(AcP). Acta Anatomica Sinica 15(2):179-184, 1984.
98. Yang G, Li Z. Histochemical studies of the SIF cells in guinea pig celiac ganglia. Acta Anatomica Sinica 14(1):86-90, 1984.
99. Li L, Chang W, Yang G, Ren C, Park S, Takahiro H, Troncoso P, Broom B, LeeSH, Lee JS, Thompson TC. Activation of c-Myb and a c-Myb-regulated DNA damage response gene program contributes to drug resistance in prostate cancer. Cancer Discovery. Submitted.
100. Karantanos T, Kurosaka S, Hirayama T, Yang G, Karanika S, Park S, Wang J, Golstov A, Tanimoto R, Li L, Thompson TC. GLIPR1-ΔTM Synergizes with Docetaxel in Cell Killing and Inhibits Resistance to Docetaxel in Prostate Cancer Cells. Molecular Cancer. Submitted.

Grant & Contract Support

Title: MD Anderson Cancer Center Prostate Cancer SPORE – Project 3: Targeting Androgen Receptor and PARP for Synthetic Lethality in CRPC
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Logothetis/Thompson
Duration: 4/1/2016 - 3/31/2021

Last updated: 9/6/2016